Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1995 1
2000 1
2002 1
2004 1
2006 1
2008 2
2009 2
2010 1
2011 1
2012 2
2013 4
2014 1
2015 4
2016 2
2017 2
2018 4
2019 7
2020 9
2021 5
2022 14
2023 7
2024 5
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Belzutifan for the treatment of renal cell carcinoma.
Wu X, Lazris D, Wong R, Tykodi SS. Wu X, et al. Among authors: tykodi ss. Ther Adv Med Oncol. 2025 Feb 8;17:17588359251317846. doi: 10.1177/17588359251317846. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 39926260 Free PMC article. Review.
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Choueiri TK, Merchan JR, Figlin R, McDermott DF, Arrowsmith E, Michaelson MD, Tykodi SS, Heath EI, Spigel DR, D'Souza A, Kassalow L, Perini RF, Vickery D, Bauer TM. Choueiri TK, et al. Among authors: tykodi ss. Lancet Oncol. 2025 Jan;26(1):64-73. doi: 10.1016/S1470-2045(24)00649-1. Lancet Oncol. 2025. PMID: 39756444 Clinical Trial.
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.
Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH Jr, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ. Choueiri TK, et al. Among authors: tykodi ss. ESMO Open. 2024 Dec;9(12):104073. doi: 10.1016/j.esmoop.2024.104073. Epub 2024 Dec 5. ESMO Open. 2024. PMID: 39642635 Free PMC article. Clinical Trial.
Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review.
Anderson AC, Ho J, Hall ET, Hannan R, Liao JJ, Louie AV, Ma TM, Psutka SP, Rengan R, Siva S, Swaminath A, Tachiki L, Tang C, Teh BS, Tsai J, Tykodi SS, Weg E, Zaorsky NG, Lo SS. Anderson AC, et al. Among authors: tykodi ss. Future Oncol. 2024;20(33):2573-2588. doi: 10.1080/14796694.2024.2389769. Epub 2024 Sep 11. Future Oncol. 2024. PMID: 39258792 Review.
72 results